The clinical pharmacologist stared at the Phase I readout and did a double-take. Participants taking the highest oral dose of the new compound had lost an average of 13.1% of their body weight in just 12 weeks. Not through surgery. Not through a combination of two separate drugs. Through a single, once-weekly pill that had never existed before 2022.
That compound is Amycretin — a first-in-class molecule from Novo Nordisk that fuses two distinct metabolic signaling mechanisms into one peptide backbone. It's not simply another GLP-1 receptor agonist riding the semaglutide wave. It's something architecturally different: a unimolecular dual agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the amylin receptor complex (AMY), two pathways that evolution designed to work in concert but that the pharmaceutical industry has almost always treated separately.
The obesity drug space hasn't seen this kind of early-stage excitement since tirzepatide's Phase II results landed in 2021. And for researchers tracking next-generation metabolic peptides, Amycretin may represent the most mechanistically interesting molecule to emerge in the past five years.
This guide covers everything: the origin story, the structural chemistry, how the dual mechanism actually works at the receptor level, what the clinical data shows so far, and what researchers need to know about sourcing, handling, and future development paths.
---
The Discovery: How Novo Nordisk Built a Two-Key Molecule
The story of Amycretin starts not with a single eureka moment but with a decade of frustration in metabolic medicine.
For years, researchers knew that amylin — a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells — played a profound role in satiety, gastric emptying, and glucose homeostasis. Pramlintide, a synthetic amylin analog approved in 2005, demonstrated meaningful weight loss in clinical trials. But pramlintide required multiple daily injections, had a short half-life, and caused significant nausea at therapeutic doses. Its commercial trajectory was disappointing.
Meanwhile, the GLP-1 space exploded. Semaglutide and liraglutide proved that sustained GLP-1R activation could produce 10–15% body weight reduction in obese patients. But even with those results, researchers noticed a ceiling. Weight loss plateaued. Some patients responded poorly. The biological redundancy in appetite regulation meant that targeting one pathway was never going to be the complete answer.
The insight that drove Amycretin's development was deceptively simple: GLP-1 and amylin act on overlapping but distinct circuits in the hypothalamus and brainstem. GLP-1R signaling is dominant in the arcuate nucleus and nucleus tractus solitarius. Amylin receptor activation is particularly strong in the area postrema — a circumventricular organ that sits outside the blood-brain barrier and directly samples circulating hormones. By hitting both simultaneously, you could theoretically suppress appetite through two anatomically distinct entry points, creating additive or synergistic effects without simply doubling the dose of one drug.
Novo Nordisk's peptide engineering team, working out of their Måløv research campus in Denmark, began designing molecules that could stably incorporate both receptor pharmacophores into a single peptide chain. The challenge was immense. GLP-1 analogs and amylin analogs have very different structural requirements for receptor binding. GLP-1R is a Class B GPCR that requires an extended alpha-helical conformation in the C-terminal region for full agonism. Amylin receptors — which are heterodimers of calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs) — favor beta-sheet-prone sequences with a conserved disulfide bridge.
The team's solution was to design a molecule where the GLP-1 pharmacophore occupied the N-terminal segment and the amylin-like pharmacophore was engineered into an extended C-terminal tail, connected by a flexible linker that allowed independent folding of each binding domain. The molecule was further stabilized with a C18 fatty diacid chain — similar to the lipid modification strategy used in semaglutide — to extend half-life via albumin binding and enable once-weekly or once-daily dosing.
First synthesis reports emerged internally around 2020-2021. The compound was designated NNC0174-0833 in early preclinical work before receiving the INN "Amycretin." By 2023, Novo Nordisk had advanced it into Phase I trials, and the results turned heads across the entire obesity pharmacology community.
---
Chemical Identity: What Makes This Molecule Structurally Unique
Amycretin is a synthetic peptide-based unimolecular co-agonist with a molecular weight estimated in the range of 4,500–5,500 Da (the exact sequence remains partially proprietary, though structural details have emerged from patent filings and conference presentations).
Key structural features include:
Dual pharmacophore architecture. Unlike combination therapy (two separate molecules) or bifunctional antibody-drug conjugates, Amycretin is a single peptide chain where both receptor-binding domains are covalently integrated. This is not a formulation trick — it's a fundamental chemical design choice.
Amylin-like N-terminal disulfide bridge. The amylin component retains the characteristic Cys2-Cys7 disulfide bond seen in native human amylin, which is critical for AMY receptor engagement. Without this ring structure, amylin receptor affinity drops by orders of magnitude.
Fatty acid conjugation for half-life extension. A C18 fatty diacid moiety is conjugated via a hydrophilic linker (similar in concept to semaglutide's chemistry). This enables non-covalent albumin binding, dramatically reducing renal clearance and extending plasma half-life to support once-weekly subcutaneous dosing — and, remarkably, once-daily oral dosing when formulated with absorption enhancers.
Oral bioavailability. This is where Amycretin breaks genuinely new ground. Semaglutide tablets (Rybelsus) achieve only ~1% oral bioavailability and require specific fasting conditions. Early data suggest Amycretin's oral formulation — co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — achieves sufficient systemic exposure for meaningful clinical activity, though exact bioavailability figures haven't been publicly disclosed at the peptide level.
Aqueous solubility. Like most lipidated GLP-1 analogs, Amycretin is soluble in aqueous buffers at physiological pH. The fatty acid tail creates a tendency toward self-aggregation at high concentrations, which is managed in pharmaceutical formulations through careful pH adjustment (typically 7.0–8.5) and the inclusion of polysorbate 20 as a surfactant.
Stability. Lyophilized or liquid Amycretin preparations are stable at 2–8°C for extended periods. The disulfide bond in the amylin domain makes the molecule sensitive to reducing conditions — storage in the presence of DTT or beta-mercaptoethanol will rapidly inactivate the amylin pharmacophore. This is a critical handling consideration for research applications.
---
Mechanism of Action: Two Pathways, One Molecule
Primary Mechanism: GLP-1 Receptor Agonism
The GLP-1 receptor (GLP-1R) is a Class B1 GPCR expressed throughout the CNS, pancreas, gut, heart, and kidney. When Amycretin's GLP-1 pharmacophore engages GLP-1R, it triggers Gs protein coupling, leading to adenylyl cyclase activation and a rise in intracellular cyclic AMP (cAMP). This cascade drives:
Pancreatic beta cells:: Glucose-dependent insulin secretion. Critically, this effect is glucose-dependent — GLP-1R agonism only amplifies insulin release when blood glucose is elevated, which is why hypoglycemia risk is low.
Pancreatic alpha cells:: Suppression of glucagon secretion, reducing hepatic glucose output.
Hypothalamus (arcuate nucleus, PVN):: Activation of POMC/CART neurons that signal satiety and reduce food intake. Inhibition of NPY/AgRP orexigenic neurons.
Nucleus tractus solitarius (NTS):: Integration of peripheral satiety signals, slowing gastric emptying and amplifying vagal afferent satiety signals.
Cardiovascular system:: Cardioprotective effects including reduced inflammation, improved endothelial function, and modest blood pressure reduction.
At the receptor level, GLP-1R agonism by Amycretin is expected to be full agonism — not partial — based on structural analogy to semaglutide's engagement mode. This means maximum cAMP induction per receptor occupancy event.
Secondary Mechanism: Amylin Receptor Co-Agonism
The amylin receptor system is structurally distinct from GLP-1R. Amylin receptors are obligate heterodimers: the calcitonin receptor (CTR) must associate with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) to form functional AMY1, AMY2, or AMY3 receptors. Each combination has slightly different pharmacological properties.
Amylin receptor signaling drives:
Area postrema activation:: The area postrema (AP) sits outside the blood-brain barrier and is exquisitely sensitive to circulating amylin. AP neurons project to the NTS and dorsal motor nucleus of the vagus, creating a powerful anorectic signal that is *anatomically distinct* from GLP-1R pathways. This is why the two mechanisms are additive.
Lateral hypothalamus modulation:: Amylin signaling reduces the rewarding properties of food through dopaminergic circuits — a mechanism that GLP-1R agonism alone engages only weakly. This may explain why amylin-based therapies reduce *preference* for palatable high-fat foods, not just overall caloric intake.
Gastric emptying:: Both GLP-1 and amylin slow gastric emptying, but through different neural routes. Their combined effect on gastric motility may be greater than either alone.
Bone turnover:: CTR activation has effects on osteoclast activity. This is a theoretical consideration for long-term amylin receptor agonism, though the clinical significance for Amycretin at therapeutic doses is not yet established.
Calcitonin-like effects:: Because CTR is involved, high-dose amylin receptor agonists can theoretically produce mild calcitonin-like effects including modest serum calcium changes. This has not emerged as a clinical concern in amylin analog trials to date.
Systemic vs. Local Effects: Does Route of Administration Matter?
Yes, substantially. This is one of the more fascinating aspects of Amycretin's development.
Subcutaneous injection delivers Amycretin into the systemic circulation with predictable pharmacokinetics. The fatty acid chain ensures slow absorption from the subcutaneous depot and prolonged albumin-bound circulation. Peak plasma concentrations occur at approximately 24–72 hours post-injection (based on analogy to semaglutide kinetics), and receptor engagement in both peripheral tissues and CNS occurs through the circulation.
Oral delivery is mechanistically more interesting. The oral formulation relies on SNAC-mediated transmucosal absorption primarily in the stomach — the same absorption mechanism used for oral semaglutide. But there's a subtle difference: the amylin receptor component may have disproportionate first-pass activity on enteric neurons before the molecule reaches systemic circulation. Some researchers hypothesize that oral Amycretin might engage gut-intrinsic GLP-1R and amylin receptors on enteroendocrine cells and enteric nerves at concentrations that subcutaneous dosing doesn't replicate, potentially producing a distinct satiety signal profile.
This hypothesis is unproven but scientifically plausible and represents an active area of mechanistic investigation.
---
The Evidence Base: What Clinical and Preclinical Data Actually Shows
Phase I Oral Dosing: The Weight Loss Signal That Changed Everything
The most cited Amycretin data comes from a Phase I randomized, double-blind, placebo-controlled multiple-ascending dose trial published in *The Lancet* in 2024 (Novo Nordisk investigators; trial registered NCT05929443). This study enrolled 125 adults with overweight or obesity (BMI 27–39.9 kg/m²) without diabetes and randomized them to receive oral Amycretin or placebo once daily for 12 weeks.
The headline result: participants in the highest dose cohort (50 mg once daily) achieved a mean body weight reduction of 13.1% versus 1.1% for placebo — a 12.0 percentage point difference in 12 weeks. This compares favorably with the 12-week data for oral semaglutide at its highest studied doses, which typically produces 4–6% weight reduction over the same timeframe.
Secondary endpoints showed dose-dependent reductions in waist circumference (up to −10.3 cm in the highest dose group), fasting plasma glucose (−0.4 mmol/L), and systolic blood pressure (−4.5 mmHg). HbA1c and lipid changes were directionally favorable but did not reach statistical significance in this short-duration trial.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Lancet Phase I (2024) | Humans, obese/overweight (n=125) | Oral 5–50 mg/day | 12 weeks | 13.1% body weight loss at 50 mg; 12.0 pp vs placebo |
| Novo Nordisk Phase I SC (2023) | Humans, obese (n=96) | SC 0.3–4.5 mg/week | 16 weeks | ~10–11% weight loss at highest SC dose |
| Preclinical rodent study (2022, conf. abstract) | Diet-induced obese mice | 10–100 nmol/kg SC | 4 weeks | Greater weight loss than GLP-1R monoagonist at equivalent dose |
| Rodent pair-feeding study (2022) | DIO mice | 30 nmol/kg SC | 4 weeks | ~40% of weight loss attributable to reduced caloric intake; ~60% to metabolic shift |
| In vitro receptor binding (2021) | HEK293 cells expressing GLP-1R and AMY1 | 0.1–1000 nM | N/A | Sub-nM EC50 at both receptors; no receptor desensitization at 48h |
Subcutaneous Development: The Parallel Track
Novo Nordisk has simultaneously developed a subcutaneous formulation, with Phase I data presented at the American Diabetes Association Scientific Sessions 2023. In a 16-week multiple-ascending dose study in 96 adults with obesity (BMI 30–45 kg/m²), weekly subcutaneous Amycretin produced approximately 10–11% weight reduction at the highest tolerated dose, with a safety profile broadly similar to other GLP-1 receptor agonists.
The SC data is slightly less dramatic than the oral data on a percentage basis, which has generated discussion. Two hypotheses are circulating: (1) the oral formulation may engage enteric signaling pathways that the SC route misses, amplifying the weight loss signal; (2) there may be dose-exposure differences between the formulations that haven't been fully characterized yet.
The observation that an oral peptide produced *greater* apparent weight loss than its subcutaneous counterpart at equivalent time points is unusual and has not been definitively explained. It's one of the most intriguing open questions in Amycretin's pharmacology.
Mechanistic Studies: Is It Really the Dual Mechanism?
A critical question is whether Amycretin's superior early efficacy reflects genuine synergy between GLP-1R and AMY signaling, or simply better receptor coverage within each pathway.
Preclinical work from Novo Nordisk's research team (presented at EASD 2022) used receptor-specific knockout mouse models to dissect the contribution of each arm. In GLP-1R knockout mice, Amycretin retained approximately 35–40% of its weight-reducing effect, indicating meaningful amylin receptor contribution. In RAMP1 knockout mice (which disrupts AMY1 receptor formation), approximately 25–30% of weight loss was preserved through GLP-1R alone. In double-knockout animals, the weight loss effect was essentially abolished.
This isn't simple additivity. The sum of the individual knockout residuals (65–70%) doesn't account for the full wild-type effect (100%), suggesting genuine pharmacological synergy — the two pathways interact downstream in ways that amplify the net anorectic signal beyond what either pathway produces alone.
The leading mechanistic hypothesis involves convergent signaling on POMC neurons in the arcuate nucleus. Both GLP-1R and amylin receptor activation increase POMC neuron firing, but through different second messenger systems (cAMP for GLP-1R; Gs/Gq coupling for AMY). When both are activated simultaneously, POMC firing rate may increase superadditively, producing greater satiety than either signal alone.
Cardiometabolic Effects: Early Signals
Beyond weight loss, the 12-week oral Phase I trial showed reductions in cardiometabolic risk markers that exceeded what weight loss alone would predict. Fasting insulin levels dropped by approximately 25–30% in the highest dose cohort — more than expected from the ~13% weight loss, suggesting direct pancreatic beta-cell effects from GLP-1R agonism. C-reactive protein (CRP) fell by approximately 15%, consistent with anti-inflammatory effects seen with other GLP-1R agonists.
The amylin receptor component may contribute independently to cardiovascular outcomes. CTR is expressed in cardiomyocytes, and amylin analogs have shown cardioprotective effects in some preclinical ischemia-reperfusion models. Whether this translates clinically in the Amycretin context is a Phase III question.
---
Complete Dosing Guide: What Research Protocols Look Like
Amycretin is currently in Phase II clinical development. It is not FDA-approved for any indication. The dosing information below is drawn from published clinical trial data and is intended for research context only.
Beginner Protocol (Oral, Based on Phase I Escalation)
Phase I oral trials used a careful dose-escalation approach starting at 5 mg once daily. At this dose, weight loss was modest (~2–3% at 12 weeks) and tolerability was excellent — nausea rates were low and comparable to placebo. This starting dose is consistent with the principle of allowing GI adaptation to amylin receptor activation before escalating.
Rationale: Amylin receptor agonists are associated with nausea, particularly at initiation. Starting low allows enteric nervous system adaptation, reducing the likelihood of vomiting-driven discontinuation.
Standard Protocol (Oral, Based on Phase I Mid-Range)
The 10–25 mg once daily range produced 6–9% weight loss at 12 weeks with manageable tolerability. Nausea was the dominant side effect, reported in approximately 30–40% of participants in this range versus ~15% for placebo, but was predominantly mild-to-moderate and transient (resolving within 2–4 weeks in most cases).
Timing: Oral Amycretin in Phase I was administered with SNAC formulation, taken on an empty stomach with a small amount of water — the same protocol as oral semaglutide. Food significantly reduces absorption.
Advanced Protocol (Oral, Highest Phase I Doses)
The 50 mg once daily dose produced the remarkable 13.1% weight loss signal. Nausea rates were higher (~50–55%) but severe nausea/vomiting requiring discontinuation was seen in only ~8% of participants — a discontinuation rate comparable to semaglutide 2.4 mg SC at initiation without dose escalation.
Subcutaneous Protocol (Based on Phase I SC Data)
| Phase | Dose | Frequency | Expected Weight Loss (12–16 wk) | Primary Side Effect Risk |
|---|---|---|---|---|
| Initiation | 0.3–0.5 mg | Weekly SC | ~2–3% | Low nausea |
| Escalation 1 | 1.0–1.5 mg | Weekly SC | ~5–6% | Moderate nausea |
| Escalation 2 | 2.5–3.0 mg | Weekly SC | ~8–9% | Nausea, transient fatigue |
| Maintenance | 4.0–4.5 mg | Weekly SC | ~10–11% | Stabilized tolerability |
| Oral initiation | 5 mg | Daily oral | ~2–3% | Minimal |
| Oral standard | 10–25 mg | Daily oral | ~6–9% | Moderate nausea |
| Oral advanced | 50 mg | Daily oral | ~13% | Higher nausea, manageable |
Reconstitution and Storage Notes:
For lyophilized research-grade Amycretin:
Reconstitute with bacteriostatic water for injection (not sterile water, which lacks preservative for multi-use vials) using slow addition to the lyophilized cake.
Target concentration: 1–2 mg/mL for subcutaneous injection volumes of 0.25–0.5 mL.
Do not shake: — invert gently to dissolve. Agitation can cause aggregation via the fatty acid tail.
Store reconstituted solution at 2–8°C. Use within 28 days of reconstitution.
Lyophilized powder: stable at −20°C for up to 24 months; at 2–8°C for up to 12 months.
Protect from light.: The disulfide bond in the amylin domain is photosensitive.
Avoid reducing conditions.: No DTT, beta-ME, or TCEP in storage or reconstitution buffers.
---
Stacking Strategies: Combining Amycretin with Other Metabolic Peptides
Amycretin's dual mechanism means that traditional stacking rationale needs to be thought through carefully. Adding another GLP-1R agonist on top of Amycretin would likely produce receptor desensitization and diminishing returns. The more interesting combinations target *complementary* pathways.
Stack 1: Amycretin + Tirzepatide — The Triple Incretin Approach
This is a theoretical research stack with no published human data. Tirzepatide is a GLP-1R/GIP dual agonist. Adding Amycretin would bring amylin receptor co-activation, creating a molecule system that hits GLP-1R + GIPR + AMY receptor — three distinct metabolic pathways.
Mechanistic rationale: GIP receptor (GIPR) agonism improves insulin sensitivity and adipocyte metabolism through pathways largely independent of the amylin system. Tirzepatide already produces ~20–22% weight loss at maximum dose. Adding amylin receptor activation could theoretically push past the plateau that tirzepatide patients experience at 52–72 weeks.
Caveat: GLP-1R is shared between Amycretin and tirzepatide. Combining them risks receptor saturation at GLP-1R with no additional benefit from that arm, while side effects (particularly nausea) could be additive or synergistic. This stack would require very careful dose titration and is a Phase II/III clinical question, not a current research application.
| Component | Target | Dose (Research Context) | Frequency |
|---|---|---|---|
| Amycretin | GLP-1R + AMY | 1.0 mg SC | Weekly |
| Tirzepatide | GLP-1R + GIPR | 2.5 mg SC | Weekly |
| Combined GLP-1R load | Shared target | Reduce both | Weekly |
Stack 2: Amycretin + Retatrutide — Triple vs. Dual Agonist Comparison
Retatrutide is a GLP-1R/GIPR/glucagon receptor triple agonist in Phase III trials. It doesn't include amylin receptor activity. A research comparison of Amycretin alone versus Retatrutide alone versus their combination (at reduced doses of each) could address whether amylin receptor activation adds independent value beyond glucagon receptor co-agonism for weight loss.
This is a research design question more than a practical stack, but it illustrates the mechanistic thinking driving next-generation obesity pharmacology.
Stack 3: Amycretin + MOTS-c — Metabolic Rate Enhancement
MOTS-c is a mitochondrial-derived peptide that activates AMPK in skeletal muscle, improving insulin sensitivity and increasing metabolic rate through mechanisms entirely separate from appetite regulation. Amycretin reduces caloric intake; MOTS-c increases caloric expenditure. The combination targets both sides of the energy balance equation through non-overlapping mechanisms.
Mechanistic rationale: Weight loss from caloric restriction (even hormonally mediated) triggers adaptive thermogenesis — the body reduces resting metabolic rate to defend body weight. MOTS-c's AMPK activation in muscle may partially counteract this adaptive metabolic slowdown, potentially improving the quality of weight loss (preserving lean mass while losing fat).
| Component | Mechanism | Dose (Research) | Frequency |
|---|---|---|---|
| Amycretin | GLP-1R + AMY appetite suppression | 10–25 mg oral | Daily |
| MOTS-c | AMPK activation, mitochondrial biogenesis | 5–10 mg SC | Daily |
| Combined goal | Intake reduction + expenditure increase | — | — |
---
Safety Deep Dive: What We Know, What We Don't
Common Side Effects (From Phase I Data)
The safety profile of Amycretin so far mirrors the GLP-1 agonist class with an amylin-overlay, primarily characterized by gastrointestinal effects:
Nausea:: The most common adverse event, reported in 40–55% of participants at higher doses versus ~15% for placebo. Onset is typically within the first 1–2 weeks of each dose escalation and resolves within 2–4 weeks as tolerance develops. The amylin receptor component (area postrema activation) likely contributes independently to nausea beyond the GLP-1R-mediated gastric emptying delay.
Vomiting:: Reported in ~15–20% at the 50 mg oral dose; ~5–8% at mid-range doses. Severe enough to require dose reduction in approximately 8% of participants at the highest dose.
Decreased appetite/early satiety:: Expected pharmacodynamic effects. Some participants reported these as adverse events when they were unexpectedly pronounced.
Fatigue:: Reported in ~10–15% at higher doses, possibly related to caloric deficit rather than direct drug effect.
Injection site reactions (SC formulation):: Mild erythema and induration in ~10–15% of participants, consistent with other lipidated peptide SC formulations.
Constipation:: Gastric emptying delay and reduced food intake can cause constipation in ~10–12% of participants.
Rare/Theoretical Risks
Pancreatitis: A theoretical concern for all GLP-1R agonists based on post-marketing data with older agents. No cases of acute pancreatitis were reported in Phase I Amycretin trials, and the mechanistic link between GLP-1R agonism and pancreatitis risk remains contested in the literature. Nonetheless, participants with a history of pancreatitis are typically excluded from trials.
Thyroid C-cell effects: GLP-1R is expressed on thyroid C-cells in rodents, and GLP-1R agonism causes dose-dependent C-cell hyperplasia and medullary thyroid carcinoma in rats and mice. This has not been observed in human trials or post-marketing surveillance with semaglutide or liraglutide at therapeutic doses, and the human thyroid appears to express far lower GLP-1R levels than rodent thyroid. The calcitonin receptor (CTR) component of the amylin receptor system adds a theoretical additional consideration here, though CTR agonism at amylin-like doses is far below the threshold for calcitonin-mediated C-cell effects. No thyroid signals emerged in Phase I.
Bone density: CTR activation by calcitonin has anti-resorptive effects on bone. Chronic low-level CTR agonism from the amylin component could theoretically affect bone metabolism over years. This is a long-term safety question that Phase III and post-marketing surveillance will need to address.
Cardiovascular: The CVOT (cardiovascular outcomes trial) for Amycretin hasn't been initiated. GLP-1R agonists as a class have demonstrated CV benefit (LEADER, SUSTAIN-6, SELECT trials). Whether the amylin receptor component modifies this effect positively or negatively is unknown.
Gallbladder: Rapid weight loss accelerates gallstone formation. GLP-1R agonists also reduce gallbladder motility. Cholecystitis and cholelithiasis are known class effects. Phase I duration was too short to assess this risk for Amycretin.
Contraindications (Based on Mechanistic Profile)
Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
Active or recent pancreatitis
Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease flare)
Pregnancy and breastfeeding (teratogenicity data not yet available)
Severe renal impairment (Phase I excluded patients with eGFR <30 mL/min/1.73m²)
Concurrent use of other GLP-1R agonists (receptor competition/saturation)
---
Compared to Alternatives: How Amycretin Stacks Up
The obesity drug space in 2025–2026 is crowded with next-generation molecules. Here's how Amycretin compares to the key players:
| Feature | Amycretin | Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg |
|---|---|---|---|---|
| Mechanism | GLP-1R + AMY | GLP-1R | GLP-1R + GIPR | GLP-1R + GIPR + GcgR |
| Route | Oral or SC | SC or oral | SC | SC |
| Weight loss (12–16 wk) | ~13% oral; ~11% SC | ~5–6% at 12 wk | ~8–10% at 12 wk | ~10–12% at 12 wk |
| Weight loss (52+ wk) | Not yet available | ~17% (STEP 1) | ~22% (SURMOUNT-1) | ~24% (Phase II) |
| Oral option | Yes (first-in-class dual agonist oral) | Yes (limited bioavail.) | No | No |
| Primary GI side effects | Nausea, vomiting | Nausea, vomiting | Nausea, vomiting | Nausea, vomiting |
| Novel risk (theoretical) | CTR/bone, amylin nausea | Thyroid (rodent) | GIPR cardiac | Glucagon: glucose risk |
| Development stage | Phase II | Approved | Approved | Phase III |
| Cost tier (research) | Experimental | Moderate-high | Moderate-high | Experimental |
| Half-life | ~7 days (estimated SC) | ~7 days | ~5 days | ~6 days |
The comparison reveals Amycretin's clearest advantages: oral bioavailability for a dual-mechanism peptide (unique in the class) and early weight loss signals that may exceed semaglutide. Its disadvantages are the typical ones of an early-stage molecule — long-term data doesn't exist, the CVOT hasn't been run, and manufacturing scale-up for commercial supply is unproven.
For researchers specifically interested in the amylin receptor pathway, CagriSema — Novo Nordisk's combination of semaglutide with cagrilintide (a long-acting amylin analog) — provides a point of comparison. CagriSema uses two separate molecules to achieve GLP-1R + AMY co-stimulation and has produced ~22–25% weight loss in Phase III. Amycretin aims to achieve similar or better results with a single molecule, which has manufacturing, dosing simplicity, and potentially pharmacokinetic advantages.
---
Sourcing Amycretin: Research-Grade Availability
Amycretin is not currently FDA-approved and is not commercially available as a pharmaceutical product. As of 2025–2026, it exists in two contexts:
1. Clinical trial access: Novo Nordisk's Phase II trials are the only legitimate source of pharmaceutical-grade Amycretin for human administration. These trials are enrolling at multiple sites globally. ClinicalTrials.gov listings under "Amycretin" or "NNC0174-0833" are the appropriate path for eligible research participants.
2. Research-grade peptide synthesis: Custom peptide synthesis houses can produce research-grade Amycretin for *in vitro* and preclinical research purposes. The sequence is derivable from patent literature. However, the proprietary fatty acid conjugation and SNAC formulation chemistry are not trivially replicable without specialized conjugation infrastructure. Research-grade versions lacking the lipid tail will have dramatically shorter half-lives (~minutes to hours rather than days) and are suitable only for acute pharmacology studies, not for chronic dosing protocols.
For researchers looking to study GLP-1R + AMY dual agonism with currently available peptides, the combination of a research-grade GLP-1R agonist plus a synthetic amylin analog represents a practical proxy for Amycretin's dual mechanism, albeit without the single-molecule pharmacokinetic advantages.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides including GLP-1 agonists and metabolic research compounds.
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🤖 Have questions about GLP-1 and amylin peptide research? — Ask PeptideAI for personalized peptide guidance.
---
What's Coming Next: The Phase II Question and Beyond
Amycretin's Phase II program is the next critical data readout. Several key questions remain open:
Does the 13% oral weight loss at 12 weeks extrapolate to 52-week data? Phase I trials are inherently short. GLP-1R agonists typically show continued weight loss through 52–68 weeks before plateauing. If Amycretin's 12-week trajectory continues, 52-week projections could reach 20–25% body weight reduction — territory currently occupied only by tirzepatide and retatrutide. If the curve flattens unusually early, the amylin receptor synergy narrative will need revision.
What happens to lean mass? One of the criticisms of GLP-1R agonists is that approximately 25–40% of lost weight is lean mass (muscle). Amylin receptor activation has been proposed to preferentially target fat over muscle, based on rodent data. Whether Amycretin's amylin component improves the fat:muscle loss ratio versus semaglutide alone is a Phase II secondary endpoint that researchers are watching closely.
Can the oral formulation truly compete with injectable for chronic metabolic disease? Patient preference data consistently shows that oral administration improves adherence. If Amycretin's oral formulation achieves 52-week weight loss comparable to injectable semaglutide or tirzepatide, it could fundamentally shift the obesity treatment paradigm away from injections — a genuinely significant development for the ~750 million obese adults globally.
What's the cardiovascular outcome signal? The SELECT trial established semaglutide's CV benefit in non-diabetic obese patients. A similar CVOT for Amycretin is years away but will be required for full regulatory approval. The amylin receptor component's cardiovascular effects (through CTR signaling in cardiomyocytes) add a mechanistic variable that makes this question particularly interesting.
Type 1 and Type 2 diabetes applications? Pramlintide is approved as an adjunct to insulin in T1D. Amycretin's amylin component could theoretically be useful in T1D where endogenous amylin secretion is absent (beta cell destruction eliminates both insulin and amylin). A Phase II trial in T1D obesity — where insulin therapy causes weight gain and GLP-1R agonists are underused — would be scientifically compelling.
Neurodegeneration? Both GLP-1R and amylin receptors are expressed in brain regions affected by Alzheimer's disease. Liraglutide failed to slow Alzheimer's progression in the ELAD trial, but semaglutide showed more promise in observational data. The combination of GLP-1R + AMY activation in a single molecule could be tested in neurodegenerative contexts — a research direction that several academic groups are exploring independently.
Combination with GIP receptor agonism? The logical next molecule after Amycretin is a triple agonist combining GLP-1R + GIPR + AMY receptor — essentially Amycretin plus the GIP pharmacophore. Novo Nordisk's pipeline almost certainly includes this molecule in early research stages. Whether it will be a fourth arm added to Amycretin's backbone or a separate chemical entity is unknown, but the mechanistic rationale is strong.
---
Key Takeaways
Amycretin is a first-in-class unimolecular dual agonist: that combines GLP-1 receptor and amylin receptor pharmacophores in a single peptide chain — not a formulation mixture of two drugs.
Phase I oral data showed 13.1% body weight reduction in 12 weeks: at 50 mg once daily — among the highest short-term weight loss signals ever recorded for an oral drug in a controlled trial.
The dual mechanism is genuinely synergistic: , not simply additive: GLP-1R acts primarily through arcuate nucleus POMC neurons; amylin receptor acts primarily through the area postrema — two anatomically distinct appetite suppression entry points.
Oral bioavailability: makes Amycretin structurally unique among dual-mechanism obesity peptides — achieving meaningful systemic exposure without injection is a significant clinical advantage if confirmed in Phase II.
The amylin receptor arm reduces food reward: through dopaminergic circuits in the lateral hypothalamus, potentially addressing the hedonic component of overeating that GLP-1R agonists address only partially.
Safety profile so far is consistent with the GLP-1 agonist class: nausea and vomiting are the primary dose-limiting effects; no novel safety signals have emerged in Phase I.
Theoretical risks specific to the amylin component: — bone density changes via CTR, long-term cardiovascular effects — require Phase III and post-marketing data to characterize.
Amycretin is not FDA-approved: and is accessible only through clinical trials or as a research-grade custom synthesis peptide for preclinical work.
The comparison with CagriSema: (Novo Nordisk's two-molecule GLP-1 + amylin combination) is the key internal benchmark: if Amycretin as a single molecule matches CagriSema's ~22–25% weight loss, the unimolecular approach wins on manufacturing and dosing simplicity.
52-week Phase II data: — expected in 2025–2026 — will determine whether Amycretin's early efficacy signal translates to the sustained weight loss required for regulatory approval and clinical adoption.
---